{
    "clinical_study": {
        "@rank": "120913", 
        "arm_group": [
            {
                "arm_group_label": "bevacizumab and trabectedin", 
                "arm_group_type": "Experimental", 
                "description": "Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients"
            }, 
            {
                "arm_group_label": "bevacizumab, trabectedin and carboplatin", 
                "arm_group_type": "Experimental", 
                "description": "Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4)  and trabectedin 3 hour iv infusion.\nCycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.\nPatient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2  ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.\nFrom cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv  and trabectedin 1.1 mg/m2 day 1 every 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is aimed at assessing the efficacy and the safety of the combination of\n      bevacizumab and trabectedin with or without carboplatin in adult women with epithelial\n      ovarian cancer at first recurrence occurred 6-12 months after the end of the first\n      platinum-containing regimen. According to the Bryant and Day design the primary endpoints\n      will be the proportion of progression-free patients at 6 months for the efficacy, and the\n      proportion of patients with severe toxicity for the safety at the same time-point."
        }, 
        "brief_title": "Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Epithelial Cancer Recurrent", 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age\u226518years\n\n          -  Eastern Cooperative Oncology Group (ECOG)- performance status 0-2\n\n          -  Cytological/histological diagnosis of epithelial ovarian cancer\n\n          -  Progression free interval between 6-12 months (calculated from the first day  of the\n             last cycle of the previous last platinum-based chemotherapy until the date of\n             progression confirmation through radiologic imaging).\n\n          -  Only one previous platinum-based chemotherapy line\n\n          -  Measurable disease according to RECIST version 1.1\n\n          -  Life expectancy \u2265 12 weeks\n\n          -  Patients must be able to receive dexamethasone or its equivalent, as a premedication\n             for trabectedin\n\n          -  Written  informed  consents  given before the enrolment according to International\n             Conference on Harmonization/ Good Clinical Practice (ICH/GCP).\n\n        Exclusion Criteria:\n\n          -  Prior treatment with trabectedin\n\n          -  Prior progression while on therapy containing bevacizumab or other vascular\n             endothelial growth factor (VEGF) pathway-target therapy\n\n          -  Pre-existing grade > 1 sensitive/motor neurologic disorder\n\n          -  Current or recent (within 30 days of first study dosing) treatment with another\n             investigational drug\n\n          -  Surgery (including open biopsy) within 4 weeks prior to the first planned dose of\n             bevacizumab\n\n          -  Current or recent (within 10 days prior to the first study drug dose) use of\n             full-dose oral or parenteral anticoagulant or thrombolytic agent for therapeutic\n             purposes (except for line patency, in which case international normalized ratio (INR)\n             must be maintained below 1.5). Post operative prophylaxis with low molecular weight\n             heparin sc is allowed\n\n          -  Inadequate bone marrow function: absolute neutrophil count (ANC): <1.5 x 109/l, or\n             platelet count <100 x 109/l or haemoglobin <9 g/dl. Patients may be transfused to\n             maintain haemoglobin values \u22659 g/dl\n\n          -  Inadequate coagulation parameters: activated partial thromboplastin time (APTT) >1.5\n             x upper limit of normal (ULN) or INR >1.5\n\n          -  Inadequate liver function, defined as: serum (total) bilirubin > ULN for the\n             institution AST/serum glutamic-oxaloacetic transaminase (SGOT) or ALT/ serum\n             glutamic-pyruvic transaminase (SGPT) >2.5 x ULN\n\n          -  Inadequate renal function: serum creatinine >1.5 mg/dL or >132 micromol/L and urine\n             dipstick for proteinuria > or = 2+ and  >1g of protein in their 24-hour urine\n             collection\n\n          -  History or evidence of brain metastases or spinal cord compression\n\n          -  Pregnant, breastfeeding women and women of child bearing potential, who do not agree\n             to use a medically acceptable method of  contraception through the treatment period\n             and for 6 months after discontinuation of treatment\n\n          -  History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular\n             accident, stroke or transient ischemic attack or sub-arachnoid haemorrhage within 6\n             months prior to the first study treatment\n\n          -  Uncontrolled hypertension (sustained systolic >150 mmHg and/or diastolic >100 mmHg\n             despite antihypertensive therapy) or clinically significant (i.e. active)\n             cardiovascular disease, including: myocardial infarction or unstable angina within 6\n             months prior to the first study treatment, New York Heart Association grade II or\n             greater congestive heart failure, serious cardiac arrhythmia requiring medication\n\n          -  History of bowel obstruction, including subocclusive disease, related to the\n             underlying disease and history of abdominal fistula, gastrointestinal perforation or\n             intra-abdominal abscess. Evidence of recto-sigmoid involvement by pelvic examination\n             or bowel involvement on CT scan or clinical symptoms of bowel obstruction\n\n          -  Non-healing wound, ulcer or bone fracture\n\n          -  hepatitis C virus (HCV) positivity\n\n          -  Other malignancy within the last 5 years, except for adequately treated carcinoma in\n             situ of the cervix or squamous carcinoma of the skin, or adequately controlled\n             limited basal cell skin cancer"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735071", 
            "org_study_id": "IRFMN-OVA-6152"
        }, 
        "intervention": [
            {
                "arm_group_label": "bevacizumab and trabectedin", 
                "description": "Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients", 
                "intervention_name": "bevacizumab and trabectedin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Avastin", 
                    "Yondelis"
                ]
            }, 
            {
                "arm_group_label": "bevacizumab, trabectedin and carboplatin", 
                "description": "Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.\nCycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.\nPatient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2  ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.\nFrom cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv  and trabectedin 1.1 mg/m2 day 1 every 21 days", 
                "intervention_name": "bevacizumab, trabectedin and carboplatin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Avastin", 
                    "Yondelis", 
                    "Carboplatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Trabectedin", 
                "Bevacizumab", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ovarian cancer", 
            "bevacizumab", 
            "trabectedin", 
            "carboplatin", 
            "randomized trial", 
            "phase II"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "contact": {
                    "email": "germanatognon@alice.it", 
                    "last_name": "Germana Tognon, Medical D"
                }, 
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Spedali Civili di Brescia"
                }, 
                "investigator": {
                    "last_name": "Germana Tognon, Medical D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nicoletta.colombo@ieo.it", 
                    "last_name": "Nicoletta Colombo, Medical D"
                }, 
                "contact_backup": {
                    "email": "sara.boveri@ieo.it", 
                    "last_name": "Sara Boveri"
                }, 
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Europeo di Oncologia"
                }, 
                "investigator": {
                    "last_name": "Nicoletta Colombo, Medical D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andreaalberto.lissoni@unimib.it", 
                    "last_name": "Andrea Lissoni, Medical D"
                }, 
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera S. Gerardo"
                }, 
                "investigator": {
                    "last_name": "Andrea Lissoni, Medical D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "a.gadducci@obgyn.med.unipi.it", 
                    "last_name": "Angiolo Gadducci, Medical D"
                }, 
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy"
                    }, 
                    "name": "Universit\u00e0 di Pisa"
                }, 
                "investigator": {
                    "last_name": "Angiolo Gadducci, Medical D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dhocc@libero.it", 
                    "last_name": "Dionyssios Katsaros, Medical D"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera S.Anna"
                }, 
                "investigator": {
                    "last_name": "Dionyssios Katsaros, Medical D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Randomized, Non-comparative, Open-label Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.", 
        "overall_contact": {
            "email": "roldano.fossati@marionegri.it", 
            "last_name": "Roldano Fossati, Medical D", 
            "phone": "00390239014467"
        }, 
        "overall_contact_backup": {
            "email": "chiara.gerardi@marionegri.it", 
            "last_name": "Chiara Gerardi, Chem Pharm D", 
            "phone": "00390239014649"
        }, 
        "overall_official": {
            "affiliation": "IRCCS Istituto Europeo di Oncologia di Milano", 
            "last_name": "Nicoletta Colombo, Medical D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: The Italian Medicines Agency", 
                "Italy: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The PFS-6, defined as the percentage of patients who are alive and progression free at 6 months after the randomization.", 
                "measure": "Progression Free Survival at 6 months (PFS-6)", 
                "safety_issue": "No", 
                "time_frame": "from randomization up to 6 months"
            }, 
            {
                "description": "The following conditions will be considered as severe toxicity:\nabsolute neutrophil count (ANC) < 0.5x109/L lasting > 7 days and/or with fever\nplatelets < 25x109/L\nany other grade 3-4 (evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 4.0) non-hematological toxicities except for reversible nausea/vomiting, diarrhea, hypersensitivity reactions, and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation reversible to grade 1 by day 28\nany toxicity causing a delay of >14 days in the following cycle", 
                "measure": "Proportion of patients with severe toxicity within 6 months from randomization.", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735071"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Defined for each patient as the time from the date of randomization to the date of first progression, second primary malignancy or death for any cause, whichever comes first. Subjects not progressed or died at the time of the analysis will be censored at the last disease assessment date.", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Defined as the percentage of patients who are alive at 12 months after the randomization.", 
                "measure": "Overall survival at 12 months (OS-12)", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "clinical benefit, defined as the percentage of patients who are judged by the Investigators to have a complete response (CR), or partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria, version 1.1 after 12 weeks from the date of randomization.", 
                "measure": "Clinical Benefit (CB)", 
                "safety_issue": "No", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Incidence of AEs, according to NCI-CTCAE, version 4.0", 
                "measure": "Incidence of Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Maximum toxicity grade experienced by each patient for each specific toxicity", 
                "measure": "Maximum toxicity grade", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Percentage of patients experiencing grade 3-4 toxicity for each specific toxicity during the study", 
                "measure": "Percentage of patients experiencing grade 3-4 toxicity for each specific toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Patients with at least a SADR during the study", 
                "measure": "Patients with at least a Serious Adverse Drug Reaction (SADR)", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Patients with at least a suspect unexpected serious adverse reaction during the study", 
                "measure": "Patients with at least a Suspect Unexpected Serious Adverse Reaction (SUSAR).", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Percentage of patients with dose and/or time modifications of the study drugs", 
                "measure": "Percentage of patients with dose and/or time modifications", 
                "safety_issue": "No", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Percentage of premature withdrawals of the enrolled patients", 
                "measure": "Percentage of premature withdrawals", 
                "safety_issue": "No", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Patients with at least a SAE during the study", 
                "measure": "Patients with at least a Serious Adverse Event (SAE)", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Nature of AEs, according to NCI-CTCAE, version 4.0", 
                "measure": "Nature of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Severity of AEs, according to NCI-CTCAE, version 4.0", 
                "measure": "Severity of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }, 
            {
                "description": "Seriousness of AEs according to NCI-CTCAE, version 4.0", 
                "measure": "Seriousness of AEs", 
                "safety_issue": "Yes", 
                "time_frame": "from randomization up to 30 months"
            }
        ], 
        "source": "Mario Negri Institute for Pharmacological Research", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "PharmaMar", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Hoffmann-La Roche", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Mario Negri Institute for Pharmacological Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}